NVO Novo Nordisk A S (NVO) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000353278
Congress · 2
Insider buyers, 180 days
0
Funds added, last quarter
685
13F, latest reported quarter
What the filings say about NVO
Congress, 1 year
2 bought · 2 sold
Latest: sale, 2026-09-10
Novo Nordisk A S insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for NOVO NORDISK A S in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Foreign private issuer: its insiders are exempt from SEC Form 4 and report in the home market, so their buys and sells do not appear here.
Insider
Filed
Shares
Value
Since filing
no insider purchases or sales on record
0 transactions on record
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
2 members bought in the last year
more than 76% of Pharma & Biotech
Funds
685 funds bought in last quarter
more than 98% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
1.2% of the float short (float per yahoo 2026-10-27) · 3.1 days to cover · settled 2026-10-15
The situation: each line is one rule over one dataset
1 clinical trial was terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch NVO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
Who owns NVO: institutional holders (13F)
13F holdings, latest reported quarter
20,397,110 sh
$977.8M
18,594,352 sh
$891.4M
13,041,109 sh
$625.2M
12,642 sh
$606.1M
11,659,869 sh
$559.0M
Congress trades in NVO
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-09-10 · disclosed 15 days later
$1,001 - $15,000
Sold 2026-08-31 · disclosed 25 days later
$1,001 - $15,000
Bought 2026-08-26 · disclosed 22 days later
$1,001 - $15,000
Sold 2025-10-31 · disclosed 21 days later
$1,001 - $15,000
Sold 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
NVO planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
NVO mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Roundhill GLP-1 & Weight Loss ETF
$7.0M position · as of 2026-06-30
13.0%
Simplify Health Care ETF
$24.2M position · as of 2026-06-30
6.8%
EuroPac International Value Fund
$12.2M position · as of 2026-07-31
6.2%
VanEck Pharmaceutical ETF
$47.2M position · as of 2026-06-30
5.4%
Port Street Quality Growth Fund
$8.2M position · as of 2026-06-30
5.2%
PROFUND VP EUROPE 30
$679.0K position · as of 2026-06-30
4.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
461 registered trials, 137 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
151
Phase 1
41 active
36
Phase 2
10 active
123
Phase 3
45 active
15
Phase 4
3 active
1
Early Phase 1
0 active
135
Not applicable
38 active
What changed recently
A Study to See How Safe a New Medicine (NNC0642-1895) is in Healthy People
2026-10-27 · Not Yet Recruiting → Recruiting
Phase 1
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With
2026-10-27 · Completion moved 2026-06-01 → 2027-01-19
Phase 1
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With
2026-10-27 · Recruiting → Active Not Recruiting
Phase 1
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Ty
2026-10-17 · Not Yet Recruiting → Recruiting
Phase 1
A Research Study Investigating How Adults With Overweight or Obesity, With or Without Ty
2026-10-17 · Not Yet Recruiting → Recruiting
Phase 1
A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult P
2026-10-14 · Recruiting → Active Not Recruiting
Phase 1
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 685 funds added last quarter, 2 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
NVO financials
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Gross profit | $250.3B | $245.9B | $196.5B | $148.5B |
| Net income | $102.4B | $101.0B | $83.7B | $55.5B |
SEC XBRL, fiscal years, as known on 2026-10-28
NVO Stock Sonar score 2/7 axes
Find similar shapesCompare2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
NVO filings, in plain words
Have members of Congress traded NVO?
Yes. In the year to 2026-10-28, 2 House members disclosed buying NVO and 2 House members disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-09-10.
Read the full summary
In the year to 2026-10-28, 2 members of Congress disclosed buying NVO and 2 members disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-09-10. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
